Mont-Saint-Guibert, Belgium – February 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which takes place March 12 – 13, 2024.
Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Tuesday, March 12, 2024, at 10:40am ET. A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website. The Company will be available for 1x1 meetings with institutional investors.
Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的?
- 大家一起关注新疆乌什7.1级地震救援见闻
- 国足13次出战亚洲杯首次小组赛0进球
- 男子“机闹”后航班取消,同机旅客准备集体起诉
- TVB老戏骨女儿与男星离婚近两年,公开与眼镜男合照高调晒恩爱
- 闹大了!女星参加浙江卫视跨年晚会丢2万元戒指,哭诉自己赔不起
- 冯小刚新片《非诚勿扰3》票房扑街,“贺岁片之王”晚节不保
- 《五福临门》新女主角吴宣仪惊艳亮相!
- 产业数字化 为何需要一朵实体云?
- 私域反哺公域一周带火一家店!
- 抖音直播“新红人”进攻本地生活领域